On September 2, 2025 Philogen reported that Dr. Samuele Cazzamalli is presenting "From DNA-encoded chemistry to ACP3-targeted radioligand therapeutics against prostate cancer" (Press release, Philogen, SEP 2, 2025, View Source [SID1234655656]). In addition, Dr. Cristiano Pini will give an update on "Diagnostic Performance, Safety, and Pharmacokinetics of [68Ga]Ga-OncoACP3 in Prostate Cancer – Preliminary Results from a Prospective Phase I Clinical Trial" and Prof. Philippp Backhaus will give a presentation on "Theranostic targeting of the prostatic acid phosphatase (ACP3) with [68Ga]Ga-OncoACP3-DOTA and [177Lu]Lu-OncoACP3-DOTA in prostate cancer patients".

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Moreover, Dr. Fabrizia Gelardi will present "First-in-Human Phase I Study of [68Ga]Ga-OncoCAIX: Preliminary Results on Safety, Dosimetry, Pharmacokinetics, and Diagnostic Performance".